The major backer of the lenacapavir roll-out is assuring nervous researchers that they will keep their part of funding promises. It's a good economic investment, says the Fund's Peter Sands, into a ...
Pharmaceutical Technology on MSN9d
Gilead’s lenacapavir applications for HIV gain EMA validationGilead Sciences has announced EMA validation for a parallel accelerated review of lenacapavir’s MAA and EU-M4all applications ...
Gilead Sciences has announced that the US Food and Drug Administration (FDA) has accepted its New Drug Application ...
Lenacapavir, a twice yearly injection that prevents HIV transmission, was named the breakthrough medicine of 2024. But ...
A multi-national, multi-institutional study led by Weill Cornell Medicine investigators found little natural resistance to a ...
The FDA has accepted under Priority Review the NDA for lenacapavir for the prevention of HIV as pre-exposure prophylaxis.
A revolutionary advancement in HIV prevention technology stands at a critical crossroads as recent policy decisions threaten ...
US antivirals giant Gilead Sciences recently announced that the US Food and Drug Administration (FDA) has accepted its New ...
Gilead Sciences has announced the European Medicines Agency’s (EMA) validation for a parallel accelerated review of lenacapavir’s marketing authorisation application (MAA) and EU-Medicines for ...
The study, published Jan. 30 in the Journal of Antimicrobial Chemotherapy, adds to growing evidence that lenacapavir may be a powerful new tool in the global anti-HIV drug arsenal.Approximately, 1 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback